Studies on normal lymphocytes, leukemic cells and cell lines indicate it is a marker for a limited segment of the B cell maturation pathway(2,3). This glycoprotein is expressed in varying degrees on normal circulating B-cells, chronic B-cell leukemia (B-CLL), prolymphocytic leukemia (PLL) and other B cell neoplasias (4–1)2. It labels the same population as CD22 antibodies but reacts with a different antigen(5). Cell reactivity: Stains peripheral blood B lymphocytes and tonsil B lymphocytes. (1).
This antibody can be used for the differentiation of PLL from B-CLL. It is also useful in confirmation of the diagnosis of other disorders such as HCL, HCL-V and SLVL. Useful for the detection of residual disease in patients undergoing treatment for these disorders.
Suitable for use in Flow Cytometry. Other applications have not been tested.
Flow Cytometry: Neat. Use 10ul per 100ul of whole blood, or 1x10e6 peripheral blood mononuclear cells (PBMC) in 100ul buffer.
Optimal dilution to be determined by the researcher.
Storage and Stability:
May be stored at 4°C for short-term only. For long-term storage and to avoid repeated freezing and thawing, add sterile glycerol (40-50), aliquot and store at -20°C. Aliquots are stable for at least 6 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
|The human B-lymphoblastoid cell line, HRIK.|
|Purified ascites. Tested by electrophoresis and Flow Cytometry.|
|Supplied as a liquid in 0.1M Tris-HCl, 0.5M sodium chloride, 10mM glycine, pH 8.0, 0.2% BSA, 0.1% sodium azide. |
|Detects a glycoprotein of 105kD found on circulating B-lymphocytes. Reacts with HRIK and Raji cell lines. Clinical Expression: B cell prolymphocytic leukemia (B-PLL): strongly positive; Hairy cell leukemia (HCL): strongly positive; Hairy cell leukemia variant (HCL-V): strongly positive; Splenic lymphoma with villous lymphocytes (SLVL): positive; B cell chronic lymphocytic leukemia (B-CLL): negative to weakly positive. No reaction with granulocytes, monocytes, platelets, erythrocytes, T lymphocytes or null cells. |
|Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.|
1. Brooks D.A., et al. 1981. J. Immunol. 26(4): 1373–1377. 2. Catovsky D., et al. 1981. Blood 58(2): 406–408. 3. Zola H., et al. 1984. J. Immunol. 133(1): 321–326. 4. Zola H., et al. 1984. In Leucocyte Typing. Ed. A. Barnard. Springer Verlag Berlin p363–371. 5. Zola H., et al. Disease Markers. 5:227–235. 6. Bloem A.C., et al. 1988. J. Immunol. 140(3):768–773. 7. Melo J.V., et al. 1988. J. Clin. Pathol. 41(9):951–959. 8. Ferro L.M. and Zola H. 1990. Immunol. 69:373–378. 9. Mulligan S.P. 1990. Leukemia and Lymphoma. 1:275–291. 10. Zola H., et al. 1991. Disease Markers. 9:103–118. 11. Burthem J. and Cawley J.C. 1994. Blood. 83(2):497–504. 12. Huh Y.O., et al. 1994. Am. J. Clin. Path. 101(3):283–289. 13. Matutes E., et al. 1994. Blood. 83(6):1558–1562. |